Eli Lilly 2003 Annual Report Download - page 8

Download and view the complete annual report

Please find page 8 of the 2003 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 100

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100

PIPELINE
6
INNOVATION FROM THE LILLY PIPELINE
Major Marketed Products
2004 Alimta® for malignant pleural mesothelioma
Symbyax™ for bipolar depression
2003 Cialis® for erectile dysfunction
(developed and marketed in joint venture with ICOS Corporation)
Strattera® for attention-defi cit hyperactivity disorder in children, adolescents, and adults
2002 Forteo® For treatment of both men and postmenopausal women with osteoporosis who
are at high risk for fracture
2001 Xigris® for adult severe sepsis patients at high risk of death
1999 Actos® for type 2 diabetes
(marketed with Takeda Chemical Industries, Ltd.)
1998 Evista® for prevention of osteoporosis in women past menopause
for treatment of osteoporosis in women past menopause (1999)
1996 Zyprexa® for schizophrenia
for acute bipolar mania (2000)
for schizophrenia maintenance (2001)
as combination therapy with lithium or valproate for acute bipolar mania (2003)
for bipolar maintenance (2004)
Humalog® for treatment of type 1 and type 2 diabetes
1995 Gemzar® for pancreatic cancer
for non-small-cell lung cancer (1998)
for bladder cancer (Europe) (2000)
for breast cancer (Europe) (2003)
ReoPro® for prevention of cardiac ischemic complications as an adjunct to percutaneous
coronary intervention (i.e., angioplasty)
(developed by Centocor, marketed by Lilly)
1987 Humatrope® for growth failure caused by pediatric growth hormone defi ciency
for replacement therapy for adult growth hormone defi ciency (1996)
for short stature caused by Turner syndrome (1997)
for idiopathic short stature (2003)
1982 Humulin® for type 1 and type 2 diabetes